KNBIF (Kane Biotech) YoY EBITDA Growth: 50.00% (As of Mar. 2026)


What is Kane Biotech YoY EBITDA Growth?

Kane Biotech KNBIF +6.51% YoY EBITDA Growth is 50.00% as of Mar. 2026. The stock has 6 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Kane Biotech's YoY EBITDA Growth for the quarter that ended in Mar. 2026 was 50.00%.

Kane Biotech's EBITDA per Share for the three months ended in Mar. 2026 was $-0.00.

Kane Biotech YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Kane Biotech's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kane Biotech YoY EBITDA Growth Chart

Kane Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -11.54 37.93 0.00 5.56 35.29

Kane Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 80.00 33.33 50.00 50.00

Kane Biotech YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Kane Biotech's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(-0.011--0.017)/ | -0.017 |
=35.29 %

Kane Biotech's YoY EBITDA Growth for the quarter that ended in Mar. 2026 is calculated as:

YoY EBITDA Growth (Q: Mar. 2026 )
=(EBITDA per Share (Q: Mar. 2026 )-EBITDA per Share (Q: Mar. 2025 )) / | EBITDA per Share (Q: Mar. 2025 )) |
=(-0.003--0.006)/ | -0.006 |
=50.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 50.00% mean?
Kane Biotech (KNBIF) has a YoY EBITDA Growth of 50.00% as of Mar. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Kane Biotech and its competitors.
Is Kane Biotech's YoY EBITDA Growth too high?
Kane Biotech's current YoY EBITDA Growth is 50.00%.
How does Kane Biotech's YoY EBITDA Growth compare to VRTX and REGN?
Kane Biotech's YoY EBITDA Growth of 50.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Kane Biotech and its competitors. Kane Biotech's current YoY EBITDA Growth is 50.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kane Biotech stock overvalued right now?
Kane Biotech (KNBIF) has a current YoY EBITDA Growth of 50.00%. The current YoY EBITDA Growth is 50.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Kane Biotech (KNBIF), the current YoY EBITDA Growth is 50.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kane Biotech Business Description

Other Exchanges KNE:Canada
Address 290-100 Innovation Drive, Winnipeg, MB, CAN, R3T 6G2
Kane Biotech Inc is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The company has a portfolio of biotechnologies, intellectual property and products developed by its own biofilm research expertise and acquired from research institutions. The company's operating segments are animal health and human health. It derives maximum revenue from Animal health segment.